KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Current Investments (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash & Current Investments for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 7.44% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 7.44% decrease, with the full-year FY2025 number at $1.5 billion, down 7.44% from a year prior.
  • Cash & Current Investments was $1.5 billion for Q4 2025 at Bio-Rad Laboratories, up from $1.4 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.9 billion in Q1 2023 to a low of $395.6 million in Q2 2023.
  • A 5-year average of $942.6 million and a median of $770.4 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 77.14% in 2023, then soared 306.57% in 2024.
  • Bio-Rad Laboratories' Cash & Current Investments stood at $476.3 million in 2021, then soared by 275.92% to $1.8 billion in 2022, then plummeted by 77.14% to $409.4 million in 2023, then skyrocketed by 306.57% to $1.7 billion in 2024, then dropped by 7.44% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Cash & Current Investments are $1.5 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).